Netherlands Cancer Institute: Winner of the ESMO Lifetime Achievement Award

July 04, 2007

The European Society for Medical Oncology (ESMO) is pleased to announce that the Netherlands Cancer Institute (NKI) is the winner of the second edition of the ESMO Lifetime Achievement Award supported by an unrestricted grant from GlaxoSmithKline (GSK).

The research group was conferred the award for its outstanding achievements in the area of Translational Research in Breast Cancer. The head of the Molecular Carcinogenesis Division of the Institute, Dr. René Bernards, and the Head of the Molecular Pathology Division, Dr. Laura van 't Veer, will receive the award on behalf of the institute during the Opening Ceremony of the ESMO Conference in Lugano (ECLU) on Thursday, 5 July 2007, 18:00-19:00, Main Auditorium, Palazzo dei Congressi Lugano, Switzerland.

From a basic genetic approach, the team of researchers at the NKI has bridged the gap to the clinic, and their contributions have resulted in the development of assays that have lead to a better understanding of breast cancer and very likely to a more precise and less aggressive therapy to patients affected with this disease.

"Last year, the ESMO Lifetime Achievement Award went to a clinical group --namely the Breast International Group (BIG)-- now recognized as a great platform for the conduct of adjuvant breast cancer trials, including the difficult ones targeting smaller molecular subgroups," said Prof. Martine Piccart, winner of the 2006 award, and current Chair of the ESMO Fellowship and Award Committee.

"This year ESMO will honor a fantastic team of basic and translational researchers from the Netherlands Cancer Institute in Amsterdam: René Bernards and Laura Van't Veer," Prof. Piccart continued. "These researchers have demonstrated exceptional skills at understanding the clinical problems cancer doctors and patients are still facing and at closing the 'gap' between the laboratory and the clinical wards. Among many achievements, they have discovered and developed a gene-signature that seems better than traditional clinical tools at targeting which breast cancer patients have an excellent prognosis and might be spared adjuvant chemotherapy."

The gene-signature has been made into a robust diagnostic product and received approval by European authorities (CE marking) and the US Food and Drug Administration (FDA, in vitro diagnostics) for daily clinical use. In addition, in Europe the gene-signature is currently being tested in a large prospective trial of the BIG group, under the leadership of EORTC: the results of this trial are expected to confirm and further improve this prognostic test. The implementation of this test into daily clinical practice, can reduce the amount of so-called adjuvant treatments with chemotherapy for (pre-menopausal) breast cancer patients by up to 30%.

The ESMO Lifetime Achievement Award has been set up to recognize the vital work carried out into research of targeted therapies and is open to all international research groups with demonstrated commitment to breast cancer treatment and research. As winner of the ESMO Lifetime Achievement Award, the Netherlands Cancer Institute will receive an independent research grant of €50,000 from ESMO to put towards their work. This award was made possible by an unrestricted educational grant from GSK.

"GSK is proud to support ESMO on this award, which aims to advance research on targeted cancer therapies - agents that are transforming the way we manage cancer and that continue to provide measurable benefits for cancer patients around the world," said Dr. Paolo Paoletti, Senior Vice President of the Oncology Medicine Development Center at GSK.

"The Netherlands Cancer Institute is becoming a real leader in the field of molecular research. The work of the team will have a strong impact on cancer treatment and ESMO is pleased to honor them with this award," said Prof. Mellstedt, ESMO President, who will personally hand over the award to the institute representatives.
About ESMO Conference Lugano (ECLU)

ECLU 2007 represents the new direction ESMO has given to the scientific and educational meeting previously known as the ESMO Summer Educational Conference (ESEC). It will be held every July under the auspices of the City of Lugano, hometown to the European Society for Medical Oncology (ESMO).

Around 1000 young oncologists, senior oncologists and cancer healthcare professionals will attend sessions on the latest developments in multidisciplinary oncology which will cover progress in cancer research and promising new technologies. International cancer specialists will highlight progress on important topics such as pharmacogenomics, molecular diagnostics, molecular-targeted therapies, new frontiers in response evaluation, cancer prevention and state-of-the-art oncology at its finest. Each Conference will also include a session on a specific topic, which in 2007 is the important issue of cancer prevention.

The 6th ESMO Patient Seminar, 7 July 2007, will also take place during ECLU. The Patient Seminar provides patients, their families and caregivers the opportunity to interact with international and local oncologists and learn more about the most recent developments and options in cancer treatment.

More information about ECLU is available at

European Society for Medical Oncology

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to